The Prenatal Genetic Counselling segmentation by application distinguishes three principal use‑cases that together drive market revenue. Risk assessment involves evaluating familial and demographic factors to estimate the probability of chromosomal or monogenic disorders, accounting for roughly 38 % of total spend as providers allocate resources to genetic history intake, risk‑model software, and counseling staff. Diagnostic testing guidance supports clinicians and patients in selecting appropriate invasive (amniocentesis, CVS) or non‑invasive (NIPT) assays; this segment commands the largest share—approximately 45 %—because it directly influences test ordering volumes, laboratory partnerships, and reimbursement pathways. Pregnancy management integrates counseling outcomes into obstetric care plans, including decisions on pregnancy continuation, specialized monitoring, and neonatal preparedness; it represents the remaining 17 % of the market, reflecting lower but growing investment in multidisciplinary care coordination and post‑test support services. Together, these application layers form the backbone of the market’s size, with each segment’s proportion reflecting its relative cost structure, service intensity, and payer acceptance.